| Literature DB >> 26294930 |
Yulian Jin1, Qing Zhao2, Kehua Zhou3, Xianghong Jing4, Xiaochun Yu4, Jiliang Fang2, Zhishun Liu5, Bing Zhu4.
Abstract
In order to investigate the therapeutic potential of acupuncture on patients with functional dyspepsia (FD), patients were randomized to receive acupuncture at classic acupoints with manipulations (treatment group) versus acupuncture at nonacupoints without manipulation (control group) once every other day, three times a week, for one month and were followed up for three months. The primary outcomes included dyspeptic symptoms, quality of life, and mental status. The secondary outcomes included the fasting serum gastrin concentration, and frequency and propagation velocity of gastric slow waves. Sixty patients with FD were included, among whom, four dropped out. After one month's treatment, patients with FD showed significant improvements in primary (in both groups) and secondary (in the eight patients of the treatment group) outcomes as compared with baseline (P = 0.0078 to <0.0001); treatment group has better outcomes in all primary outcome measures (P < 0.0001 except for SDS (P = 0.0005)). Improvements on dyspeptic symptoms persist during follow-up (better in the treatment group). Acupuncture with manual manipulation had better effects on improving dyspeptic symptoms, mental status, and quality of life in patients with FD. These effects may be related to the increased frequency and propagation speed of gastric slow waves and serum gastrin secretion.Entities:
Year: 2015 PMID: 26294930 PMCID: PMC4534622 DOI: 10.1155/2015/904926
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flow chart of study participation.
General characteristics of patients with FD prior to participation.
| Groups | Cases ( | Gender | Age (year) | Disease duration (years) | Dyspeptic symptom sum score | SF-36 score | |
|---|---|---|---|---|---|---|---|
| Male ( | Female ( | ||||||
| Treatment | 28 | 11 | 17 | 49.29 ± 10.32 | 12.20 ± 12.20 | 24.32 ± 8.28 | 52.51 ± 13.94 |
| Control | 28 | 10 | 18 | 48.25 ± 11.40 | 12.11 ± 10.20 | 24.79 ± 7.48 | 54.06 ± 16.41 |
|
| 0.7825 | 0.7229 | 0.6145 | 0.8265 | 0.7043 | ||
Scores of dyspeptic symptoms, quality of life, and mental status before and after the treatment.
| Items | Groups |
| Baseline | After treatment | Difference | Improvement rate |
|
|---|---|---|---|---|---|---|---|
| PF | Treatment | 28 | 9.00 ± 2.09 | 1.57 ± 2.28 | 7.43 ± 2.47 | 82.56% | <0.0001 |
| Control | 27 | 8.89 ± 2.39 | 6.22 ± 2.59 | 2.67 ± 1.88 | 30.03% | <0.0001 | |
| IGC | <0.0001 | ||||||
|
| |||||||
| ES | Treatment | 19 | 9.74 ± 1.91 | 0.42 ± 1.43 | 9.32 ± 1.97 | 95.69% | <0.0001 |
| Control | 21 | 8.43 ± 2.87 | 6.05 ± 2.52 | 2.38 ± 1.80 | 28.23% | <0.0001 | |
| IGC | <0.0001 | ||||||
|
| |||||||
| EP | Treatment | 21 | 6.81 ± 2.23 | 0.48 ± 1.03 | 6.33 ± 2.31 | 92.95% | <0.0001 |
| Control | 22 | 7.41 ± 3.02 | 6.32 ± 3.41 | 1.09 ± 1.82 | 14.71% | 0.0078 | |
| IGC | <0.0001 | ||||||
|
| |||||||
| EBS | Treatment | 16 | 6.31 ± 2.39 | 0.50 ± 1.55 | 5.81 ± 2.17 | 92.08% | <0.0001 |
| Control | 17 | 6.71 ± 2.78 | 6.47 ± 3.00 | 0.24 ± 0.56 | 3.58% | 0.25 | |
| IGC | <0.0001 | ||||||
|
| |||||||
| DSSS | Treatment | 28 | 24.32 ± 8.28 | 2.50 ± 3.28 | 21.80 ± 8.24 | 89.72% | <0.0001 |
| Control | 28 | 24.79 ± 7.48 | 19.40 ± 8.23 | 5.36 ± 3.29 | 21.62% | <0.0001 | |
| IGC | <0.0001 | ||||||
|
| |||||||
| SF-36 | Treatment | 28 | 52.50 ± 13.94 | 70.00 ± 12.54 | 17.00 ± 14.04 | 33.52% | <0.0001 |
| Control | 28 | 54.00 ± 16.41 | 56.00 ± 13.42 | 2.88 ± 8.74 | 5.33% | 0.0099 | |
| IGC | <0.0001 | ||||||
|
| |||||||
| SDS | Treatment | 28 | 57.96 ± 9.55 | 45.60 ± 8.75 | 12.30 ± 9.89 | 21.33% | <0.0001 |
| Control | 28 | 57.60 ± 11.84 | 54.00 ± 10.80 | 3.50 ± 5.92 | 6.07% | 0.0002 | |
| IGC | 0.0005 | ||||||
|
| |||||||
| SAS | Treatment | 28 | 52.30 ± 10.48 | 42.30 ± 6.22 | 10.00 ± 10.22 | 19.11% | <0.0001 |
| Control | 28 | 52.36 ± 9.67 | 52.20 ± 7.98 | 0.11 ± 4.89 | 0.21% | 0.8533 | |
| IGC | <0.0001 | ||||||
PF: postprandial discomfort; ES: early satiety; EP: epigastric pain; EBS: epigastric burning sensation; DSSS: dyspeptic symptom sum score; SF-36: short-form 36 questionnaire; SDS: Self-Rating Depression Scale; SAS: Self-Rating Anxiety Scale; IGC: intergroup comparison.
Dyspeptic symptom sum score at baseline and during follow-up.
| IND | Groups |
| Baseline | Follow-up | Difference | Improvement |
|
|---|---|---|---|---|---|---|---|
| DSSS | Treatment | 28 | 24.32 ± 8.28 | 1.68 ± 2.36 | 22.60 ± 8.68 | 93.09% | <0.0001 |
| Control | 28 | 24.79 ± 7.48 | 16.43 ± 7.41 | 8.36 ± 6.58 | 33.92% | <0.0001 | |
| IGC | <0.0001 |
DSSS: dyspeptic symptom sum score; IGC: intergroup comparison.
Serum gastrin concentration and frequency and propagation velocity of gastric slow waves in patients with functional dyspepsia and healthy adults.
| Items | Baseline ( | After treatment ( | Healthy adults ( |
|---|---|---|---|
| Gastrin (pg/mL) | 25.93 ± 5.90 | 44.40 ± 6.26 | 47.65 ± 20.21 |
| FGSW (n/min) | 2.49 ± 0.64 | 3.11 ± 0.14 | 3.11 ± 0.13 |
| PVGSW (s) | 24.25 ± 4.95 | 19.75 ± 2.05 | 19.41 ± 0.93 |
FGSW: frequency of gastric slow waves; PVGSW: propagation velocity of gastric slow waves.
Note: propagation velocity of gastric slow waves was assessed by the time interval between two consecutive waves that passed through the gastric antrum.
Comparisons of serum gastrin concentration and frequency and propagation velocity of gastric slow waves before and after treatment as well as between patients with functional dyspepsia and healthy adults.
| Items | Baseline versus healthy adults | Baseline versus after treatment | After treatment versus healthy adults |
|---|---|---|---|
| Gastrin | 0.0081 | 0.0002 | 0.6401 |
| FGSW | 0.0008 | 0.0078 | 1.0000 |
| PVGSW | 0.0279 | 0.0180 | 0.6713 |
FGSW: frequency of gastric slow waves; PVGSW: propagation velocity of gastric slow waves.
Note: propagation velocity of gastric slow waves was assessed by the time interval between two consecutive waves that passed through the gastric antrum. “Baseline versus after treatment” refers to patients with functional dyspepsia only.